X

Trial Profile

A prospective observational multicentre study to evaluate immunogenicity, efficacy, and safety of BNT162b2 mRNA vaccine in Israel

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 12 Jan 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tozinameran (Primary)
Indications COVID 2019 infections
Focus Pharmacodynamics

Most Recent Events

21 Jun 2021 Primary endpoint has been met. (Immunogenicity of the BNT162b2 mRNA vaccine in adult patients with AIIRD compared with controls measured 26 weeks after the second vaccine dose) , according to Results published in the Annals of the Rheumatic Diseases
21 Jun 2021 New trial record
14 Jun 2021 Results published in the Annals of the Rheumatic Diseases

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com